SCHEDULE 13G/A: Adage Capital Management Discloses 8.78% Stake in Abeona Therapeutics
Beneficial Ownership Disclosure
Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have disclosed a beneficial ownership of 8.78% in Abeona Therapeutics Inc., totaling 4,411,572 shares, including warrants.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 4,411,572 shares of Abeona Therapeutics Inc. Common Stock.
- This ownership represents 8.78% of the company's outstanding Common Stock.
- The reported amount includes 1,719,944 shares of Common Stock that are issuable upon the exercise of warrants.
- The percentage is calculated based on 48,533,798 shares of Common Stock outstanding as of March 11, 2025, as reported in Abeona Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The filing is an Amendment No. 9 to a Schedule 13G, indicating an update to a previously reported position.
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not convey explicit positive or negative sentiment. A score of 5 indicates neutrality.
Industry Context
This filing indicates a significant institutional investment in Abeona Therapeutics, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common for large investors taking or updating positions in publicly traded companies, reflecting their investment strategies within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a prominent institutional investor like Adage Capital Management can influence investor perception and potentially market sentiment regarding Abeona Therapeutics' stock.
Key Dates
| Date | Description |
|---|---|
| 2025-03-11 | Date as of which the number of outstanding shares of Common Stock (48,533,798) was reported in the Company's 10-K. |
| 2025-03-20 | Date Abeona Therapeutics Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires filing of this statement. |
| 2025-05-12 | Date the Schedule 13G Amendment No. 9 was signed and filed. |
Keywords
Abeona Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals, Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.